ArticleInnovation (Cambridge (Mass.))2026
Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes.
Article in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Younger donors are preferred in allogeneic hematopoietic stem cell transplantation (allo-HSCT), but this preference may limit access for patients whose only available donors are older. This study evaluated whether donor leukocyte telomere length (LTL), in conjunction with donor age, refines donor selection strategies to improve outcomes in recipients with acute leukemia. The discovery analysis included 1,049 acute leukemia patients who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine, while the replication cohort included 153 recipients from three additional centers. Donor LTL was measured using real-time quantitative PCR and categorized into quartiles: short (Q1) and long (Q2-Q4). Donor age was prespecified as <40 (younger) vs. ≥40 (older) years based on clinical practice. Long donor LTL was associated with a lower cumulative incidence of relapse (CIR), improved overall survival (OS), and better relapse-free survival (RFS) in allo-HSCT recipients. Recipients of grafts from donors aged ≥40 years with short LTL had higher CIR (adjusted hazard ratio [aHR] = 1.51; 95% confidence interval [CI], 1.04-2.19), worse OS (aHR = 1.76; 95% CI, 1.20-2.58), and worse RFS (aHR = 1.53; 95% CI, 1.06-2.20) compared with recipients of grafts from donors <40 years. Immune cell profiling showed that older donors with short LTL had more CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.